SCOPE
Journal of Immunotherapy is a peer reviewed, multidisciplinary journal directed to an audience of immunotherapy and biological therapy physicians and researchers. The journal publishes original articles in the form of basic studies, clinical studies, and selected abstracts from scientific meetings and conferences.
Ethical/Legal Considerations
A submitted manuscript must be an original contribution not previously published (except as an abstract or preliminary report), must not be under consideration for publication elsewhere, and, if accepted, must not be published elsewhere in similar form, in any language, without the consent of Lippincott Williams & Wilkins. Each person listed as an author is expected to have participated in the study to a significant extent. Although the editors and referees make every effort to ensure the validity of published manuscripts, the final responsibility rests with the authors, not with the Journal, its editors, or the publisher.
All manuscripts must be submitted on-line through the journal's Web site at
http://www.editorialmanager.com/jit/default.aspx. See submission instructions below, under "On-line manuscript submission."
Patient anonymity and informed consent:
It is the author's responsibility to ensure that a patient's anonymity be carefully protected and to verify that any experimental investigation with human subjects reported in the manuscript was performed with informed consent and following all the guidelines for experimental investigation with human subjects required by the institution(s) with which all the authors are affiliated. Authors should mask patients' eyes and remove patients' names from figures unless they obtain written consent from the patients and submit written consent with the manuscript.
Copyright:
All authors must sign a copy of the Journal's "Authorship Responsibility, Financial Disclosure, and Copyright Transfer" form and submit it at the time of manuscript submission.
Conflicts of interest:
Authors must state all possible conflicts of interest in the manuscript, including financial, consultant, institutional and other relationships that might lead to bias or a conflict of interest. If there is no conflict of interest, this should also be explicitly stated as none declared. All sources of funding should be acknowledged in the manuscript. All relevant conflicts of interest and sources of funding should be included on the title page of the manuscript with the heading “Conflicts of Interest and Source of Funding:”. For example:
Conflicts of Interest and Source of Funding: A has received honoraria from Company Z. B is currently receiving a grant (#12345) from Organization Y, and is on the speaker’s bureau for Organization X – the CME organizers for Company A. For the remaining authors none were declared.
In addition, each author must complete and submit the journal's copyright transfer agreement, which includes a section on the disclosure of potential conflicts of interest based on the recommendations of the International Committee of Medical Journal Editors, "Uniform Requirements for Manuscripts Submitted to Biomedical Journals" (www.icmje.org/update.html).
A copy of the form is made available to the submitting author within the Editorial Manager submission process. Co-authors will automatically receive an Email with instructions on completing the form upon submission.
Open access
Authors of accepted peer-reviewed articles have the choice to pay a fee to allow perpetual unrestricted online access to their published article to readers globally, immediately upon publication. Authors may take advantage of the open access option at the point of submission. Please note that this choice has no influence on the peer review and acceptance process. These articles are subject to the journal's standard peer-review process and will be accepted or rejected based on their own merit.
The article processing charge (APC) is charged on acceptance of the article and should be paid within 30 days by the author, funding agency or institution. Payment must be processed for the article to be published open access. For a list of journals and pricing please visit our
Wolters Kluwer Open Health Journals page.
Authors retain copyright
Authors retain their copyright for all articles they opt to publish open access. Authors grant Wolters Kluwer an exclusive license to publish the article and the article is made available under the terms of a Creative Commons user license. Please visit our Open Access Publication Process page for more information.
Creative Commons license
Open access articles are freely available to read, download and share from the time of publication under the terms of the Creative Commons License Attribution-NonCommerical No Derivative (CC BY-NC-ND) license. This license does not permit reuse for any commercial purposes, nor does it cover the reuse or modification of individual elements of the work (such as figures, tables, etc.) in the creation of derivative works without specific permission.
Compliance with funder mandated open access policies
An author whose work is funded by an organization that mandates the use of the Creative Commons Attribution (CC BY) license is able to meet that requirement through the available open access license for approved funders. Information about the approved funders can be found here: http://www.wkopenhealth.com/inst-fund.php
It is the responsibility of the author to inform the Editorial Office and/or LWW that they have RCUK funding. LWW will not be held responsible for retroactive deposits to PMC if the author has not completed the proper forms.
Compliance with National Institutes of Health Accessibility Requirements
The National Institutes of Health (NIH) requires authors to submit the “post-print” (the final manuscript, in Word format, after peer-review and acceptance for publication but prior to the publisher’s copyediting, design, formatting, and other services) of research the NIH funds to a repository that is accessible online by all without charge. As a service to our authors, LWW will identify to the National Library of Medicine (NLM) articles that require deposit and will transmit the post-print of an article based on research funded in whole or in part by the NIH to PubMed Central.
FAQ for open access
https://www.wolterskluwer.com/en/solutions/lippincott-journals/lippincott-open-access/faq
Permissions:
Authors must submit written permission from the copyright owner (usually the publisher) to use direct quotations, tables, or illustrations that have appeared in copyrighted form elsewhere, along with complete details about the source. Any permissions fees that might be required by the copyright owner are the responsibility of the authors requesting use of the borrowed material, not the responsibility of Lippincott Williams & Wilkins.
Electronic manuscript submission: On-line manuscript submission:
All manuscripts must be submitted on-line through the new Web site at
http://editorialmanager.com/jit.Artificial Intelligence (AI) Authoring Tools
Authors who use AI tools in the writing of a manuscript, production of images or graphical elements of the paper, or in the collection and analysis of data, must be transparent in disclosing in the Materials and Methods (or similar section) of the paper how the AI tool was used and which tool was used. Authors are fully responsible for the content of their manuscript, even those parts produced by an AI tool, and are thus liable for any breach of publication ethics.
First-time users:
Please click the Register button from the menu above and enter the requested information. On successful registration, you will be sent an e-mail indicating your user name and password. Print a copy of this information for future reference. Note: If you have received an e-mail from us with an assigned user ID and password, or if you are a repeat user, do not register again. Just log in. Once you have an assigned ID and password, you do not have to re-register, even if your status changes (that is, author, reviewer, or editor). Authors: Please click the log-in button from the menu at the top of the page and log in to the system as an Author. Submit your manuscript according to the author instructions. You will be able to track the progress of your manuscript through the system. If you experience any problems, please contact:
Managing Editor
Patrick Wall
Fax: 215-827-5586
Email: [email protected]
Requests for help and other questions will be addressed in the order received. Manuscripts that do not adhere to the following instructions will be returned to the corresponding author for technical revision before undergoing peer review.
Brief Communication:
Articles having a maximum of 1500 words and an abstract with a highly focused message and minimum of methodological detail, and maximum of 15 references. Include "Brief Communication" in the title.
Case reports should include an up-to-date review of previous cases in the field. Case reports should be no more than 2000 words long, with up to 10 references and 3 figures. Each case report should include the following sections: Title page including author details, Abstract, Case presentation, Discussion, References and Figures (optional).
Title page:
Include on the title page (a) complete manuscript title; (b) authors' full names and affiliations; (c) name and address for correspondence, including fax number, telephone number, and e-mail address; (d) address for reprints if different from that of corresponding author; and (e) sources of support that require acknowledgment.
The title page must also include disclosures of funding received for this work from any of the following organizations: National Institutes of Health (NIH); Wellcome Trust; Howard Hughes Medical Institute (HHMI); and other(s)
Unstructured abstract and key words:
Limit the abstract to 250 words. It must be factual and comprehensive. Limit the use of abbreviations and acronyms, and avoid general statements (eg, "the significance of the results is discussed"). List three to five key words or phrases.
Text:
Organize the manuscript into four main headings: Introduction, Materials and Methods, Results, and Discussion. Define abbreviations at first mention in text and in each table and figure. If a brand name is cited, supply the manufacturer's name and address (city and state/country). Acknowledge all forms of support, including pharmaceutical and industry support, in an Acknowledgments paragraph.
Abbreviations:
For a list of standard abbreviations, consult the American Medical Association Manual of Style, 9th edition (available from the American Medical Association, 515 N. State Street, Chicago, IL 60610 or other standard sources. Write out the full term for each abbreviation at its first use unless it is a standard unit of measure.
Supplemental Digital Content
Supplemental Digital Content (SDC):
Authors may submit SDC via Editorial Manager to LWW journals that enhance their article's text to be considered for online posting. SDC may include standard media such as text documents, graphs, audio, video, etc. On the Attach Files page of the submission process, please select Supplemental Audio, Video, or Data for your uploaded file as the Submission Item. If an article with SDC is accepted, our production staff will create a URL with the SDC file. The URL will be placed in the call-out within the article. SDC files are not copy-edited by LWW staff, they will be presented digitally as submitted. For a list of all available file types and detailed instructions, please visit
http://links.lww.com/A142.
SDC Call-outs
Supplemental Digital Content must be cited consecutively in the text of the submitted manuscript. Citations should include the type of material submitted (Audio, Figure, Table, etc.), be clearly labeled as "Supplemental Digital Content," include the sequential list number, and provide a description of the supplemental content. All descriptive text should be included in the call-out as it will not appear elsewhere in the article.
Example:
We performed many tests on the degrees of flexibility in the elbow (see Video, Supplemental Digital Content 1, which demonstrates elbow flexibility) and found our results inconclusive.
List of Supplemental Digital Content
A listing of Supplemental Digital Content must be submitted at the end of the manuscript file. Include the SDC number and file type of the Supplemental Digital Content. This text will be removed by our production staff and not be published.
Example:
Supplemental Digital Content 1. wmv
SDC File Requirements
All acceptable file types are permissible up to 10 MBs. For audio or video files greater than 10 MBs, authors should first query the journal office for approval. For a list of all available file types and detailed instructions, please visit
http://links.lww.com/A142.
References:
The authors are responsible for the accuracy of the references. Key the references (double-spaced) at the end of the manuscript. Cite the references in text in the order of appearance. Cite unpublished data—such as papers submitted but not yet accepted for publication and personal communications, including e-mail communications—in parentheses in the text. If there are more than three authors, name only the first three authors and then use et al. Refer to the List of Journals Indexed in Index Medicus for abbreviations of journal names, or access the list at
http://www.nlm.nih.gov/tsd/serials/lji.html. Sample references are given below:
Journal article
1. Mocellin S, Wang E, Marincola FM. Cytokines and immune response in the tumor microenvironment. J Immunother. 2001;24:392–407.
Book chapter
2. Linehan WM, Zbar B, Bates SE, et al. Cancer of the kidney and ureter. In: DeVita VT Jr, Helman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. 6th ed. Philadelphia, PA: Lippincott Williams & Wilkins, 2001:1362–1396.
Entire book
3. Rosenberg SA. Principles and Practice of the Biologic Therapy of Cancer. 3rd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2000.
Software
4. Epi Info [computer program]. Version 6. Atlanta: Centers for Disease Control and Prevention; 1994.
Online journals
5. Friedman SA. Preeclampsia: a review of the role of prostaglandins. Obstet Gynecol [serial online]. January 1988;71:22–37. Available from: BRS Information Technologies, McLean, VA. Accessed December 15, 1990.
Database
6. CANCERNET-PDQ [database online]. Bethesda, MD: National Cancer Institute; 1996. Updated March 29, 1996.
World Wide Web
7. Gostin LO. Drug use and HIV/AIDS [JAMA HIV/AIDS Web site]. June 1, 1996. Available at: http://www.ama-assn.org/special/hiv/ethics. Accessed June 26, 1997.
Figures:
A) Creating Digital Artwork
1. Learn about the publication requirements for Digital Artwork: http://links.lww.com/ES/A42
2. Create, Scan and Save your artwork and compare your final figure to the Digital Artwork Guideline Checklist (below).
3. Upload each figure to Editorial Manager in conjunction with your manuscript text and tables.
B) Digital Artwork Guideline Checklist
Here are the basics to have in place before submitting your digital artwork:
• Artwork should be saved as TIFF, EPS, or MS Office (DOC, PPT, XLS) files.
• Crop out any white or black space surrounding the image.
• Diagrams, drawings, graphs, and other line art must be vector or saved at a resolution of at least 1200 dpi. If created in an MS Office program, send the native (DOC, PPT, XLS) file.
• Photographs, radiographs and other halftone images must be saved at a resolution of at least 300 dpi.
• Photographs and radiographs with text must be saved as postscript or at a resolution of at least 600 dpi.
• Each figure must be saved and submitted as a separate file. Figures should not be embedded in the manuscript text file.
Remember:
• Cite figures consecutively in your manuscript.
• Number figures in the figure legend in the order in which they are discussed.
• Upload figures consecutively to the Editorial Manager web site and enter figure numbers consecutively in the Description field when uploading the files.
Figure legends:
Include legends for all figures. They should be brief and specific, and they should appear on a separate manuscript page after the text. Use scale markers in the image for electron micrographs, and indicate the type of stain used.
Color figures:
The journal accepts for publication color figures that will enhance an article. Authors who submit color figures will receive an estimate of the cost for color reproduction. If they decide not to pay for color reproduction, they can request that the figures be converted to black and white at no charge.
Tables:
Create tables using the table creating and editing feature of your word processing software (eg. Word, WordPerfect). Do not use Excel or comparable spreadsheet programs. Cite tables consecutively in the text, and number them in that order. Each table should appear as a separate page, and should include the table title, appropriate column heads, and explanatory legends (including definitions of any abbreviations used). Do not embed tables within the body of the manuscript. They should be self-explanatory and should supplement, rather than duplicate, the material in the text.
Style:
Pattern manuscript style after the American Medical Association Manual of Style (9th edition). Stedman's Medical Dictionary (27th edition) and Merriam Webster's Collegiate Dictionary (10th edition) should be used as standard references. Refer to drugs and therapeutic agents by their accepted generic or chemical names, and do not abbreviate them. Use code numbers only when a generic name is not yet available. In that case, supply the chemical name and a figure giving the chemical structure of the drug. Capitalize the trade names of drugs and place them in parentheses after the generic names. To comply with trademark law, include the name and location (city and state in USA; city and country outside USA) of the manufacturer of any drug, supply, or equipment mentioned in the manuscript. Use the metric system to express units of measure and degrees Celsius to express temperatures, and use SI units rather than conventional units.
After Acceptance
Electronic Page Proofs and Corrections
Corresponding authors will receive electronic page proofs to check the copyedited and typeset article before publication. Portable document format (PDF) files of the typeset pages and support documents (e.g., reprint order form) will be sent to the corresponding author via e-mail. Complete instructions will be provided with the e-mail for downloading and marking the electronic page proofs. Corresponding author must provide an email address. The proof/correction process is done electronically.
It is the author's responsibility to ensure that there are no errors in the proofs. Changes that have been made to conform to journal style will stand if they do not alter the authors' meaning. Only the most critical changes to the accuracy of the content will be made. Changes that are stylistic or are a reworking of previously accepted material will be disallowed. The publisher reserves the right to deny any changes that do not affect the accuracy of the content. Authors may be charged for alterations to the proofs beyond those required to correct errors or to answer queries. Proofs must be checked carefully and corrections faxed within 24 to 48 hours of receipt, as requested in the cover letter accompanying the page proofs.
Reprints.
Authors will receive an email notification with a link to the order form soon after their article publishes in the journal (https://shop.lww.com/author-reprint). Reprints are normally shipped 6 to 8 weeks after publication of the issue in which the item appears. Contact the Reprint Department, Lippincott Williams & Wilkins, 351 W. Camden Street, Baltimore, MD 21201; Fax: 410.558.6234; E-mail: [email protected] with any questions.
